Paxlovid, an antiviral against Covid still too little prescribed

by time news
Between February and October 2022, 54,200 people were prescribed the antiviral Paxlovid. FABIAN SOMMER/dpa Picture-Alliance via AFP

DECRYPTION – In addition to vaccines, it is the only one to have confirmed its ability to reduce the risk of a serious form in infected patients.

Covid cases and hospitalizations have been on the rise for the past fortnight. To cope with this new wave, vaccination remains more relevant than ever. But it has been a few months since the vaccine is no longer the only way to fight against serious forms of the disease: since last January, treating physicians can indeed prescribe an antiviral, Paxlovid, in patients at risk of a serious form. of the disease. But too few still benefit from it…

Between February and October 2022, 54,200 people were prescribed this drug, according to the latest data from the public structure of expertise in the epidemiology of health products Epi-Phare, published on Monday. A use that quadrupled between July and October compared to the period from February to June. But, if the prescriptions increase sharply, they remain well below the level they should reach. “We had a complicated start and we are struggling to fill…

This article is for subscribers only. You have 78% left to discover.

Pushing back the limits of science is also freedom.

Keep reading your article for €0.99 for the first month

Already subscribed? Login

You may also like

Leave a Comment